about
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaPreclinical rare cancer research to inform clinical trial designThe molecular origin and taxonomy of mucinous ovarian carcinomaCX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerImmunotherapy of Ipilimumab and Nivolumab in patients with advanced neuroendocrine tumours: a subgroup analysis of the CA209-538 clinical trial for rare cancers
P50
description
researcher
@en
wetenschapper
@nl
name
Clare L Scott
@en
Clare L Scott
@nl
type
label
Clare L Scott
@en
Clare L Scott
@nl
prefLabel
Clare L Scott
@en
Clare L Scott
@nl
P31
P496
0000-0002-3689-5956